Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Rosetta Genomics Reports 2015 Full Year Financial Results
-
Notable Analyst Rating Changes 12/21: AGR) (CIEN) (AVGO) Upgraded; (DDR) (WTR) (ERIC) Downgraded
-
UPDATE: Cantor Fitzgerald Starts Rosetta Genomics (ROSG) at Spec. Buy
-
Pre-Open Stock Movers 12/18 (GMLP) (ROSG) (RHT) Higher; (KNX) (ICPT) (KMX) Lower (more...)
-
Rosetta Genomics Reports Financial Results for the First Half of 2015
-
Rosetta Genomics Announces Participation in Cantor Fitzgerald’s Inaugural “From Bench to Bedside” Healthcare Conference
-
UPDATE: Cantor Fitzgerald Upgrades Rosetta Genomics (ROSG) to Buy
-
Pre-Open Stock Movers 04/17: (CE) (UNXL) (MAT) Higher; (ATHX) (DSCO) (AMD) Lower (more...)
-
Rosetta Genomics Reports 2014 Financial Results
-
Unusual 11 Mid-Day Movers 2/18: (CAPN) (ANGI) (MSN) Higher; (VRNS) (ROSG) (FOSL) Lower
-
Cantor Fitzgerald Starts Rosetta Genomics (ROSG) at Hold
-
Rosetta Genomics (ROSG) Enters $10M Ordinary Share Controlled Equity Offering
-
Unusual 11 Mid-Day Movers 9/9: ENCO, VVUS, CLZR, HITK, DPTR Higher; OPXA, LRN, ROSG, ELOS Lower
-
Cantor Fitzgerald Downgrades Rosetta Genomics (ROSG) to Hold; Higher Execution Risk

